- Home
- WSBK vs IOBT Comparison
WSBK vs IOBT Comparison
Compare WSBK & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSBK
- IOBT
- Stock Information
- Founded
- WSBK 2024
- IOBT 2014
- Country
- WSBK United States
- IOBT Denmark
- Employees
- WSBK N/A
- IOBT N/A
- Industry
- WSBK
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- WSBK
- IOBT Health Care
- Exchange
- WSBK NYSE
- IOBT Nasdaq
- Market Cap
- WSBK 87.0M
- IOBT 79.7M
- IPO Year
- WSBK N/A
- IOBT 2021
- Fundamental
- Price
- WSBK $8.80
- IOBT $1.29
- Analyst Decision
- WSBK
- IOBT Strong Buy
- Analyst Count
- WSBK 0
- IOBT 3
- Target Price
- WSBK N/A
- IOBT $9.33
- AVG Volume (30 Days)
- WSBK 30.7K
- IOBT 233.4K
- Earning Date
- WSBK 01-01-0001
- IOBT 08-12-2025
- Dividend Yield
- WSBK N/A
- IOBT N/A
- EPS Growth
- WSBK N/A
- IOBT N/A
- EPS
- WSBK 0.02
- IOBT N/A
- Revenue
- WSBK $15,687,000.00
- IOBT N/A
- Revenue This Year
- WSBK N/A
- IOBT N/A
- Revenue Next Year
- WSBK N/A
- IOBT N/A
- P/E Ratio
- WSBK $531.16
- IOBT N/A
- Revenue Growth
- WSBK N/A
- IOBT N/A
- 52 Week Low
- WSBK $8.76
- IOBT $0.66
- 52 Week High
- WSBK $10.10
- IOBT $1.73
- Technical
- Relative Strength Index (RSI)
- WSBK N/A
- IOBT 49.63
- Support Level
- WSBK N/A
- IOBT $1.26
- Resistance Level
- WSBK N/A
- IOBT $1.57
- Average True Range (ATR)
- WSBK 0.00
- IOBT 0.13
- MACD
- WSBK 0.00
- IOBT -0.04
- Stochastic Oscillator
- WSBK 0.00
- IOBT 19.46
About WSBK WINCHESTER BANCORP INC
Winchester Bancorp Inc provides a variety of financial services to individuals and small businesses through its offices in Winchester, Woburn, Danvers and Arlington, Massachusetts. Its primary deposit products are checking, savings and term certificate accounts and its primary lending products are residential and commercial real estate loans.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.